of the Drexel University School of Medicine. At that point, the patient underwent “surgical debulking” of his tumor. The pathology specimen confirmed the diagnosis of GBM and that the patient’s tumor ...

The US regulator has approved Tibsovo (ivosidenib) in combination with Bristol-Myers Squibb's chemotherapy Vidaza (azacitidine) as a first-line therapy for IDH1-mutated acute myeloid leukaemia ...

for IDH1-mutant acute myeloid leukaemia to the US market. It also shares commercial rights to BMS’ Idhifa (enasidenib), also for AML, and according to Bloomberg the two drugs should bring in ...

And this update only applies to people with IDH1/2 mutant glioma. Perhaps ... This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of ...